Regulatory approval

Published by the Health Service Executive.

The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with cyclophosphamide, etoposide, prednisolone, and vincristine for reimbursement as a treatment option for the treatment of Non Hodgkin CD20 positive Lymphoma for patients not suitable for anthracycline therapy.

This is written in the approval document as:

Treatment of Non Hodgkin CD20 positive Lymphoma for patients not suitable for anthracycline therapy.

Citation

R-CEOP Therapy - 21 days, 2021, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/510-r-ceop-therapy.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine